• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Chronic Organ Transplant Rejection Report Highlights How Anti Rejection Therapies Provide Satisfactory Efficacy but Their Side Effect Profiles Are a Safety Concern

Posted on: Wednesday, 19 March 2008, 09:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c86371) has announced the addition of Decision Resources report "Chronic Organ Transplant Rejection: Opportunities Await Improved Therapies" to their offering.

Introduction

The organ transplant market, though growing only slowly in recent years, offers substantial opportunities for drug developers. This market encompasses therapies that must be taken lifelong, ensuring a steady stream of revenue throughout a drug's life cycle. Another attractive feature of this market is that it can serve as a gateway to other, potentially more lucrative markets.

Get the Answers You Need to Shape Your Strategy

Although the organ transplant market has seen slow growth, certain segments - of the market offer greater opportunities. What factors are constraining this market? Will growth accelerate in coming years? Which markets offer the greatest potential rewards?

- Current anti-rejection therapies provide satisfactory efficacy, but their side-effect profiles are a safety concern. Which current therapies are associated with the most serious effects? What are the greatest unmet needs in this market? How can companies capitalize on these needs as they develop new therapies?

- Two leading agents in this market, Astellas's Prograf and Roche/Chugai's Cellcept, will soon go off-patent. What will the advent of increased generic competition mean for the market? Which agents will become the new market leaders?

Scope

- Biology of transplant rejection: immune response in tissue rejection, natural killer cell response, types of rejection, post-transplant survival rates.

- Prevalence of organ transplantation: number of transplants performed per year (including projections through 2017), number of transplants per organ, number of transplants by age-group.

- Current therapies: treatment after transplantation, commonly used maintenance therapies.

- Market for anti-rejection therapies: emerging therapies, long-acting tacrolimus, CP-690550, belatacept.

- Market outlook: drivers, constraints, development strategies.

Contents:

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Biology of Transplant Rejection

Immune Response in Tissue Rejection

T-Cell Activation

B-Cell Activation

Natural Killer Cell Response

Types of Rejection

Importance of HLA Matching in Preventing Organ Rejection

Post-Transplant Survival Rates

Prevalence of Organ Transplantation

Current Therapies

Treatment After Organ Transplantation

Overview of Commonly Used Agents for Maintenance Therapy

Azathioprine

Corticosteroids

Cyclosporine

Mycophenolate

Sirolimus

Tacrolimus

2007 Market for Anti-Rejection Therapies

Emerging Therapies and Their Commercial Potential

Long-Acting Tacrolimus

CP-690550

Belatacept

Outlook: Drivers, Constraints, and Development Strategies

Tables

1. Immune System Mediators and Their Functions

2. U.S. Sales of Leading Branded Agents (Organ Transplant Market Only) to

Prevent Organ Rejection, 2007

3. Agents in U.S. Development for the Prevention of Chronic Rejection, 2007

Figures

1. Number of U.S. Organ Transplantations, 1988-2017

2. Number of U.S. Organ Transplants, by Organ, 2007

3. Mechanism of Action of Current Anti-Rejection Agents

4. U.S. Market Growth of Anti-Rejection Agents, 2000-2007

5. U.S. Market Share of Leading Anti-Rejection Agents, 2007

6. U.S. Prescribing Share of Leading Anti-Rejection Agents, 2007

For more information visit http://www.researchandmarkets.com/reports/c86371

Source: Business Wire

More News in this Category